Description
Aadi Bioscience is a clinical-stage biopharmaceutical company. The Company is engaged in developing precision therapies for genetically defined cancers.
It develops therapies for cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. Its lead product, FYARROTM, is an mTOR inhibitor bound to human albumin that has tumor accumulation, mTOR target suppression, and tumor growth inhibition over other mTOR inhibitors in preclinical models2.
Its nab platform allows for intratumoral drug accumulation and mTOR target suppression (pS6) at equal doses for FYARROTM vs oral mTOR inhibitors resulting in higher anti-tumor activity in animal models. Its product, FYARROTM, is in phase II registrational trial for nab-sirolimus, ABI-009 in patients with advanced perivascular epithelioid cell tumors (PEComa).
